Sanofi S.A., FR0000120578

Wall Street Zen downgrades Sanofi stock to Hold

Published on 10/05/2026 at 10:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi and Regeneron will develop four antibodies worth up to USD 8.00 billion. Sanofi stock costs EUR 71.12 on October 5, 2026 after EUR 71.12.

Isometric 3D render of a translucent violet-blue cube containing a glowing molecular structure, a vaccine vial, a tablet blister pack, and a laboratory microscope — Sanofi FR0000120578 isometric 3D violet cube enclosing molecular structure, vaccine vial, blister pack, and microscope, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000120578) was trading at EUR 71.12 at Lang & Schwarz on October 5, 2026 at 10:01 a.m. CEST, unchanged versus the prior close of EUR 71.12. On October 3, 2026, MarketBeat reported that Wall Street Zen downgraded Sanofi from Buy to Hold.

Wall Street Zen changes its rating

The rating change follows a major pipeline decision. Sanofi and Regeneron agreed to develop four next-generation antibodies, creating a potential deal value of USD 8.00 billion.

The Business Standard reported on October 2, 2026 that Sanofi will pay USD 1.00 billion upfront, with another USD 7.00 billion tied to potential milestones. The companies will share development costs and future profits equally, while Regeneron leads research and Sanofi handles global sales if the medicines are approved.

Four antibodies reshape the deal

Sanofi said in its investor-relations release dated October 1, 2026 that the expanded alliance includes long-acting immunology antibodies. One candidate, REGN20423, is in early-stage testing for atopic dermatitis, while the other three are expected to begin clinical testing in 2027.

The transaction offers Sanofi access to additional immunology assets, but the USD 8.00 billion headline value is contingent on development and commercial milestones. That structure makes the USD 1.00 billion upfront payment the clearest near-term financial commitment.

Quarterly figures and the next date

In quarterly results reported on July 30, 2026, MarketBeat cited revenue of USD 13.36 billion, up 16.00 percent year over year, while earnings per share fell to USD 2.41 from USD 3.24. The comparison captures the central investor tension: revenue growth is running alongside lower per-share earnings.

Sanofi's investor calendar schedules third quarter 2026 results for October 30, 2026, with management set to review the figures in a live webcast. That update should provide the next dated test of pipeline spending, sales growth and the company's response to long-term Dupixent patent pressure.

Sanofi stock at EUR 71.12

Sanofi was trading at EUR 71.12 at Lang & Schwarz on October 5, 2026 at 10:01 a.m. CEST, unchanged versus the EUR 71.12 prior close at Lang & Schwarz dated October 2, 2026. Global Banking & Finance Review identifies Sanofi's primary listing as SAN.PA on Euronext Paris and confirms the FR0000120578 ISIN.

The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.